3rd ESTRO Forum 2015 S69 reconstruction algorithms have been implemented using 'The Reconstruction ToolKit ' (RTK), an open source C++ library based on 'The Insight ToolKit' (ITK). Results: Data from a patient admitted for lung cancer and imaged with the Elekta Synergy cone-beam CT has been reconstructed with all four reconstruction methods. The figure shows a coronal slice extracted from each of the volumes.
Purpose/Objective: Heterogeneous uptake of contrast agent during Dynamic Contrast Enhanced -MRI experiments is often found in patients with locally advanced cervical cancer. The information obtained from the heterogeneous enhancement within the tumor is likely to reflect distinct domains of different underlying tissue characteristics. The hierarchical structure of a set of kinetic models may be based on the general 2-Compartment eXchange Model (2CXM). Under limiting condition this generic model may be simplified to the Tofts model (TM) (weakly vascularized), the Extended Tofts model (ETM) (highly perfused) and the Compartmental Tissue-Uptake model (C-TU) (uptake regime). The aim of this study was to evaluate the ability of a set of nested kinetic models to classify sub-volumes within cervix cancer tumor tissue. The correlation of model selection to tumor stage was investigated.
Materials and Methods:
In brief, 15 cervical cancer patients with advanced stages (FIGO: IIA/IIB/IIIB/IVA -1/9/4/1) underwent DCE-MRI prior to radiotherapy. DCE-MRI was performed using a 3T Philips Achieva scanner and a threedimensional (3D) saturation recovery spoiled gradient echo technique with 20-24 slices having a 5 mm slice thickness, TR/TE of 2.9/1.4 ms, Tsat of 25ms, flip angle (FA) of 10°, inplane resolution 2.3 mm x 2.3 mm and 2.1 s time resolution. The bolus injected was 0.1 mmol/kg Dotarem at 4 ml/s, followed by a 50 ml saline flush. A total of 120 dynamic scans were obtained of which 18 time-points were scanned before the bolus arrived at the iliac arteries. A T1 relaxation map was constructed before contrast injection. The nested set of kinetic models included 2CXM, C-TU, ETM and TM. The model which described best the temporal contrast agent concentration profile (i.e. best fit) was identified using the corrected Akaike Information Criteria. For the kinetic analysis a population based input function using a similar injection profile was applied. For statistical inference a one sided non-parametric Wilcoxon rank-sum test was employed with the significance level of p<0.05.
Results:
The main observation was the ability of the hierarchical tracer kinetic model sub-volume classification to detect distinct contiguous regions within the tumor. The division of the tumors into the nested set of kinetic model, measured by median and interquartile range (IQR) of volume fraction were; TM: 23.4% (12.4% -32.4%), ETM: 7. 4% (4.6% -16.4%), C-TU: 27.9% (17.6% -37.9%) and 2CXM: 40.5% (24.6% 43.0%). There was a significant difference (p=0.01) in the percentage volume best described by TM between patients with tumor stage ≤IIB (10 pts) and tumor stage ≥IIIB (5 pts) (Fig. 1. ). The volume fractions described by the remaining models were not found to differ significantly between the stage groups. Conclusions: Firstly, we found that the hierarchical kinetic classification approach was able to identify contiguous regions within tumor tissue in patients with locally advanced cervical cancer. Secondly, it was seen that patients with the most advanced stages (≥IIIB) tended to be overly expressing regions of TM DCE-MRI enhancement profiles. 
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Conclusions:
The measure of the diffusion properties of water in prostate carcinoma and in the healthy prostate tissue, before and after curative radiation therapy, is able to characterize the response to the irradiation. This study indicated that Diffusional Kurtosis is a promising biomarker for evaluation of tumour response to radiation therapy and can be used for follow-up. Major progress in modern oncological treatment over the last decades has turned cancer increasingly into a more chronic and less life threatening disease and has led to an increasing number of cancer survivors. Therefore, in addition to classical clinical endpoints in cancer studies like survival, disease control rates and physician assessed morbidity, health-related quality of life and patient reported outcomes have considerably gained importance, as many patients have to face potential impairments for a long time. Furthermore, the increasing use of highly effective combined treatments raises concerns about the impact of morbidity on patients' quality of life. In comparison, patient reported outcomes represent a subjective evaluation in terms of quantifying frequency and/or intensity of symptoms and/or their impact on activities of daily life. They are assessed directly from the patient, mainly with questionnaires and without any clinical interpretation [Basch et al. 2012] . Therefore, they provide the most direct feedback reflecting the patients' experience with disease and treatment and are increasingly recognized as reliable and valid endpoints in clinical studies. Several reports in literature indicate substantial variations between physician assessed morbidity and patient reported symptoms, mainly suggesting underreporting of milder to moderate symptoms in physician assessed morbidity [Fromme et al. 2004 , Vistad et al. 2008 , Davidson et al. 2007 , Velikova et al. 2001 , Kirchheiner et al. 2012 . From a methodological point of view, comparisons are restricted, as the physician assessed grading system and the answer categories of patient reported symptoms in a questionnaire do not follow a linear association. Nevertheless, it has been shown that discrepancies are frequently observed, if the patient reports substantial symptoms, which are not recognized by the physician in the
